Diranersen demonstrates increasing clinical benefit at two years in early Alzheimer’s disease

Diranersen demonstrates increasing clinical benefit at two years in early Alzheimer’s disease




Diranersen demonstrates increasing clinical benefit at two years in early Alzheimer’s disease

– Diranersen slowed clinical decline by 38% on CDR-SB at two years (Week 96) with the 60 mg twice-yearly regimen, corresponding to a 1.09-point treatment difference –

– Greater slowing of clinical decline across 5 of 6 measures at two years compared with 18 months (Week 76) in the 60 mg dose group –

– Clinical benefits were observed across all doses studied, with the 60 mg dose group showing compelling efficacy and a favorable benefit-risk profile –

– Data presented at the Clinical Trials on Alzheimer’s Disease (CTAD) conference –

CARLSBAD, Calif.–(BUSINESS WIRE)–Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that its partner, Biogen, shared new data from the Phase 2 CELIA study showing increasing clinical benefit of diranersen, an investigational antisense oligonucleotide (ASO) therapy targeting tau, in people living with early Alzheimer’s disease at two years (Week 96). Results presented at the Clinical Trials on Alzheimer’s Disease (CTAD) 2026 conference showed slowing of clinical decline across measures of cognition, function and disease progression, with the 60 mg twice-yearly regimen showing the largest treatment effects at two years.


“The diranersen data presented at CTAD underscore the potential of our RNA-targeted technology to achieve meaningful reductions in tau and reinforce the promise of tau-lowering as a therapeutic approach for people living with early Alzheimer’s disease,” said Holly Kordasiewicz, Ph.D., executive vice president, chief development officer, Ionis. “The sustained and deepening clinical benefits are encouraging and we are proud to partner with Biogen.”

At two years, analyses showed that diranersen continued to slow clinical decline across measures of cognition, function and disease progression. Clinical benefits were observed across all doses studied, with the 60 mg twice-yearly regimen showing the largest treatment effects at two years. Diranersen was generally well tolerated through two years, with no new safety signals observed.

Clinical outcomes with the 60 mg twice-yearly regimen (n=60) versus participants originally randomized to placebo (n=115)

Week 76

Week 96

CDR-SB

26%

38%*

ADAS-Cog13

42%

54%

MMSE

50%

38%

ADCS-ADL-MCI

0%

30%

ADCOMS

23%

38%

Modified iADRS

30%

46%

* Corresponding to a 1.09-point treatment difference on CDR-SB at Week 96

The two-year analyses were derived from the ongoing open-label extension phase of CELIA. Treatment effects were calculated by comparing participants who received diranersen during the placebo-controlled phase of the study and remained on the same dose through two years with participants who were initially assigned to placebo and transitioned into the extension phase. At Week 96, participants in the placebo group had received either no doses or a single dose of diranersen following their transition into the extension phase, providing a placebo-equivalent comparator. All participants in the extension phase are expected to receive diranersen as the study progresses.

Alongside the two-year results, Biogen presented new 18-month placebo-controlled clinical and biomarker findings from CELIA that further support the effects of diranersen. At 18 months, the twice-yearly 60 mg diranersen sub-group analysis showed preferential efficacy in memory, orientation, and executive function. Diranersen also robustly reduced tau PET signal broadly across the brain, CSF p-tau181, and plasma p-tau217.

These data build on previously reported results from the Phase 2 CELIA study and further support the continued development of diranersen for people living with early Alzheimer’s disease.

About diranersen (IONIS-MAPTrx/BIIB080)

Diranersen (IONIS-MAPTrx/BIIB080) is an investigational antisense oligonucleotide (ASO) therapy designed to target microtubule-associated protein tau (MAPT) mRNA to reduce the production of tau protein. Unlike many investigational approaches that have focused on targeting extracellular tau, diranersen is designed to reduce both intracellular and extracellular tau.

Diranersen is being investigated as a potential treatment for early Alzheimer’s disease. In 2025, the U.S. Food and Drug Administration (FDA) granted Fast Track designation to diranersen for the treatment of Alzheimer’s disease.

In December 2019, Biogen exercised a license option with Ionis Pharmaceuticals and obtained a worldwide, exclusive, royalty-bearing license to develop and commercialize diranersen. Diranersen was discovered by Ionis.

About the CELIA Study

CELIA is a global Phase 2 randomized, double-blind, placebo-controlled, dose-ranging study evaluating the efficacy, safety, and tolerability of diranersen in individuals with early Alzheimer’s disease. The study enrolled 416 participants with mild cognitive impairment due to Alzheimer’s disease or mild Alzheimer’s disease dementia. All participants enrolled in CELIA had not previously received anti-amyloid therapy.

The study evaluated three doses of diranersen administered intrathecally over an 18-month placebo-controlled treatment period: 60 mg every six months, 115 mg every six months, and 115 mg every three months.

The primary endpoint of CELIA was assessment of dose response for change from baseline on the Clinical Dementia Rating–Sum of Boxes (CDR-SB) at Week 76. Secondary and exploratory endpoints included additional clinical, biomarker, and imaging measures, including cerebrospinal fluid tau biomarkers and tau positron emission tomography (PET). Additional information on the study design is available in the ClinicalTrials.gov listing for the CELIA study.

An ongoing long-term extension (LTE) study is continuing to evaluate the long-term safety, tolerability, and durability of diranersen’s clinical benefit in early Alzheimer’s disease.

About Ionis Neurology

Ionis has been at the forefront of discovering and developing leading neurological disease medicines, including ZANVASTRO™ (zilganersen), the only approved treatment for Alexander disease, SPINRAZA® (nusinersen), the first approved treatment for spinal muscular atrophy, WAINUA® (eplontersen), a medicine to treat hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN), and QALSODY® (tofersen) for SOD1-ALS. The clinical-stage portfolio includes 11 investigational medicines, of which seven are wholly owned by Ionis. Ionis’ investigational portfolio includes medicines for which there are few or no disease modifying treatments, such as rare diseases including Angelman syndrome, prion disease and multiple system atrophy, as well as more common conditions like Alzheimer’s disease.

About Ionis Pharmaceuticals, Inc.

For more than three decades, Ionis has invented medicines that bring better futures to people with serious diseases. Ionis currently has marketed medicines and a leading pipeline in neurology, cardiometabolic disease and select areas of high patient need. As the pioneer in RNA-targeted medicines, Ionis continues to drive innovation in RNA therapies in addition to advancing new approaches in gene editing. A deep understanding of disease biology and industry-leading technology propels our work, coupled with a passion and urgency to deliver life-changing advances for patients. To learn more about Ionis, visit Ionis.com and follow us on X (Twitter), LinkedIn and Instagram.

Ionis Forward-looking Statements

This press release includes forward-looking statements regarding Ionis’ business and the therapeutic and commercial potential of diranersen, our commercial medicines, additional medicines in development and technologies and our expectations regarding development and regulatory milestones. Any statement describing Ionis’ goals, expectations, financial or other projections, intentions or beliefs is a forward-looking statement and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties including those inherent in the process of discovering, developing and commercializing medicines that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such medicines. Ionis’ forward-looking statements also involve assumptions that, if they never materialize or prove correct, could cause its results to differ materially from those expressed or implied by such forward-looking statements. Although Ionis’ forward-looking statements reflect the good faith judgment of its management, these statements are based only on facts and factors currently known by Ionis. Except as required by law, we undertake no obligation to update any forward-looking statements for any reason. As a result, you are cautioned not to rely on these forward-looking statements. These and other risks concerning Ionis’ programs are described in additional detail in Ionis’ annual report on Form 10-K for the year ended December 31, 2025 and most recent Form 10-Q, which are on file with the Securities and Exchange Commission. Copies of these and other documents are available from the Company.

In this press release, unless the context requires otherwise, “Ionis,” “Company,” “we,” “our” and “us” all refer to Ionis Pharmaceuticals and its subsidiaries.

Ionis Pharmaceuticals® is a trademark of Ionis Pharmaceuticals, Inc. ZANVASTRO™ is a trademark of Ionis Pharmaceuticals, Inc. QALSODY® and SPINRAZA® are registered trademarks of Biogen. WAINUA® is a registered trademark of the AstraZeneca group of companies.

Contacts

Ionis Investor Contact:
D. Wade Walke, Ph.D.

IR@ionis.com
760-603-2331

Ionis Media Contact:
Hayley Soffer

Media@ionis.com
760-603-4679

SKAN takes note of the Federal Criminal Court’s first-instance judgments

SKAN AG

/ Key word(s): Statement

SKAN takes note of the Federal Criminal Court’s first-instance judgments

17.11.2026 / 17:54 CET/CEST


Media Information

SKAN takes note of the Federal Criminal Court’s first-instance judgments

Allschwil, 17 November 2026 – SKAN Group AG takes note of today’s first-instance judgments of the Federal Criminal Court. The Head of the Services, Digital & Single-Use Systems Segment was acquitted of the charge of exploiting insider information.

The CFO has given notice of appeal against the first-instance conviction. This means that the proceedings against him have not yet been legally concluded. The presumption of innocence continues to apply, and he remains in his position. SKAN Group AG has the greatest interest in the ongoing proceedings being concluded as quickly as possible. The Board of Directors continues to monitor the situation closely.

Contacts:

Thomas Balmer, ir@skan.com, +41 79 703 87 28
Alexandre Müller, ir@skan.com, +41 79 635 64 13

Financial calendar:

28 January 2027 Publication of preliminary key figures for the 2026 financial year
23 March 2027 Publication Annual Results 2026
28 April 2027 Annual General Meeting 2027

 

SKAN – together always one step ahead

SKAN is a pioneer in the field of aseptic and aseptic-toxic manufacturing processes for the (bio)pharmaceutical industry. The company is the market and technology leader for high-quality, process-critical isolator systems for filling drugs according to strict sterility standards. In addition, the company offers its customers process support, software, services and single-use systems. Innovative solutions and a customer-focused life-cycle support organisation make SKAN an important partner for the pharmaceutical and biotech industry, CMOs (Contract Manufacturing Organisations) and research laboratories worldwide. Founded in 1968, SKAN today employs around 1700 people. About half of them work at the Allschwil headquarters in the Life Sciences Hub of the Basel region. The other employees are located among the subsidiaries in Switzerland, Germany, Belgium, France, Slovenia, Croatia, Japan, the USA and Brazil.


End of Media Release


Language: English
Company: SKAN AG
Kreuzstrasse 5
4123 Allschwil
Switzerland
Phone: +41 43 268 32 32
E-mail: info@skan.com
ISIN: CH0013396012
Valor: 1339601
Listed: SIX Swiss Exchange
EQS News ID: 2437110

 
End of News EQS News Service

2437110  17.11.2026 CET/CEST

MindMaze Therapeutics Announces CHF 4 Million Financing

MindMaze Therapeutics Holding SA / Key word(s): Financing

MindMaze Therapeutics Announces CHF 4 Million Financing

17-Nov-2026 / 07:00 CET/CEST

Release of an ad hoc announcement pursuant to Art. 53 LR

The issuer is solely responsible for the content of this announcement.


MindMaze Therapeutics Announces CHF 4 Million Financing

Geneva, Switzerland – November 17, 2026 – MindMaze Therapeutics (SIX: MMTX) (the Company), a global leader in scalable precision neurotherapeutics, today announced that it has signed agreements securing investment commitments of up to CHF 4 million from long-term strategic investors. The proceeds will support the wider commercial deployment of its neurotherapeutics platform.

With clinically validated solutions already in use and a commercial organization in place, the Company aims to expand its customer base and accelerate revenue growth across its portfolio. This includes increasing adoption among healthcare providers and broadening access to rehabilitation at home, supported by the launch of MindMotion Lite, a tablet-based solution designed for home deployment.

“We appreciate our investors’ confidence in our ability to scale and their support through their investment and networks,” said Zach Henderson, Chief Executive Officer of MindMaze Therapeutics. “This funding allows us to build on our existing deployments and continue bringing precision neurotherapeutics to more patients.”

The agreements provide for CHF 3 million in funding scheduled for November and December 2026, subject to customary closing conditions. Either party may also exercise an additional CHF 1 million investment option until February 28, 2027. The financing comprises primarily shares and mandatory convertible notes priced at CHF 0.12 per share, subject to a limited market-based adjustment. It includes 7 million five-year warrants at CHF 0.25 per share—a 79% premium to the previous day’s closing price—plus 2.5 million on the same terms if the option is exercised, and 1.28 million five-year warrants at CHF 0.12.

The Company also reported it has agreed to terminate the remaining unfunded commitment of CHF 4 million under the financing announced on May 26, 2026.

About MindMaze Therapeutics
MindMaze Therapeutics (SIX: MMTX) is a global leader in scalable, precision neurotherapeutics, dedicated to redefining the recovery trajectory for patients around the world. By integrating advanced software, proprietary sensors, and AI-driven data analytics, MindMaze Therapeutics provides a seamless continuum of care from the acute hospital phase to outpatient treatment to home-based therapy. The company’s FDA-listed and CE-marked products are designed to address the systemic shortage of specialized clinicians, offering scalable, reimbursable solutions for stroke, Parkinson’s disease, and other neurological disorders. With an extensive library of rigorous clinical validation, MindMaze Therapeutics is operationalizing the future of neurorestorative medicine. For more information, visit www.mindmazetherapeutics.com.

Media & Investor Contacts
Jeremy Meinen, Chief Financial Officer
ir@mindmazetherapeutics.com

DISCLAIMER
This press release contains forward-looking statements, which may be identified by words such as “believe,” “assume,” “expect,” “intend,” “may,” “could,” “will,” or similar expressions. These statements are based on current plans and assumptions and are subject to risks and uncertainties that could cause actual results, financial condition, performance, or achievements to differ materially from those expressed or implied. This communication is provided as of the date hereof, and MindMaze Therapeutics undertakes no obligation to update any forward-looking statements contained herein as a result of new information, future events or otherwise.

Additional features:

File: Ad hoc release_MindMaze_Financing November 2026


End of Inside Information


Language: English
Company: MindMaze Therapeutics Holding SA
Avenue de Secheron 15
1202 Geneva
Switzerland
Phone: +41 22 545 11 16
Fax: +41 22 545 11 17
E-mail: ir@mindmazetherapeutics.com
Internet: www.mindmazetherapeutics.com
ISIN: CH1251125998
Listed: SIX Swiss Exchange
EQS News ID: 2436290

 
End of Announcement EQS News Service

2436290  17-Nov-2026 CET/CEST

Two Blockbusters, Two Niche-Busters, One Smart Portfolio: Formycon Names Tezspire® and Hemlibra® as Reference Drugs

Formycon AG

/ Key word(s): Miscellaneous

Two Blockbusters, Two Niche-Busters, One Smart Portfolio: Formycon Names Tezspire® and Hemlibra® as Reference Drugs

17.11.2026 / 06:30 CET/CEST

The issuer is solely responsible for the content of this announcement.


Press Release // November 17, 2026

 

Two Blockbusters, Two Niche-Busters, One Smart Portfolio: Formycon Names Tezspire® and Hemlibra® as Reference Drugs

 

  • FYB210: biosimilar candidate to tezepelumab (Tezspire®); sales of the reference drug rose by 50 percent to USD 1.9 billion in 2025
  • FYB286: biosimilar candidate to emicizumab (Hemlibra®); no biosimilar approved so far in the US or Europe for bispecific antibodies like this one

 

Planegg-Martinsried, Germany – Formycon AG (FSE: FYB, Prime Standard, “Formycon”), an independent developer of biosimilars, names the reference drugs of its biosimilar candidates FYB210 and FYB286: FYB210 is a biosimilar candidate to tezepelumab (Tezspire®1), FYB286 to emicizumab (Hemlibra®2). Both are niche-busters, that is, drugs for niche indications with global annual sales in the low- to mid-single-digit billion US dollar range. Together with Keytruda®3 (FYB206) and Dupixent®4 (FYB208), four reference drugs of the Formycon pipeline have now been named: two blockbusters and two niche-busters with annual sales of between USD 1.9 billion and USD 31.7 billion.5

Dr. Stefan Glombitza, CEO of Formycon AG, said: “With FYB210 and FYB286, we aim to make two therapies for serious diseases accessible to more people. Tezepelumab, the active ingredient of FYB210, helps people with severe asthma and is currently being studied in COPD, the third leading cause of death worldwide. Emicizumab, the active ingredient of FYB286, reduces the risk of potentially life-threatening bleeding events in people with hemophilia A. For bispecific antibodies like this one, no biosimilar has yet been approved in the United States or Europe. We can take on projects like these because Formycon is among the world’s leading biosimilar developers.”

 

FYB210: biosimilar candidate to tezepelumab

 

Tezepelumab is the first approved antibody targeting thymic stromal lymphopoietin (TSLP), a signaling protein at the top of several inflammatory cascades. The drug is approved as an add-on therapy for severe asthma and, since 2025, also for chronic rhinosinusitis with nasal polyps. Its global sales rose by 50 percent to USD 1.9 billion in 2025.6 Further indications are being studied in Phase III clinical trials, among them chronic obstructive pulmonary disease (COPD), the third leading cause of death worldwide according to the WHO.7 Analysts expect peak annual sales of more than USD 4 billion.8

 

FYB286: biosimilar candidate to emicizumab, a bispecific antibody

 

Emicizumab is used to prevent or reduce bleeding episodes in people with hemophilia A, the most common form of hemophilia. In 2017, the US Food and Drug Administration (“FDA”) approved emicizumab as the first bispecific antibody outside oncology. A bispecific antibody binds two targets at once. This places particular demands on the development, manufacturing and analytical characterization of a biosimilar. More than a dozen bispecific antibodies are approved in the United States. To date, no biosimilar to any of these antibodies has been approved in either the United States or Europe.

 

Global sales of the drug rose by 11 percent at constant exchange rates to CHF 4.8 billion (equivalent to USD 5.7 billion) in 2025.9 In many regions, the medical need remains unmet: according to estimates of the World Federation of Hemophilia, more than 75 percent of people with hemophilia worldwide have not yet been diagnosed.10

 

Formycon is developing FYB286 in cooperation with Biocelys, which contributes its manufacturing infrastructure. Santo Biosimilar is financing the project upfront. Both companies belong to the Athos Group, the largest shareholder of Formycon. Formycon receives arm’s-length compensation for its development services and participates in the future revenues of Santo with a low double-digit percentage share (release of October 21, 2026).

 

Smart Portfolio and development status

 

The mix of blockbusters and niche-busters is the core of the Smart Portfolio, one of the four pillars of the growth strategy FYB4Growth. FYB206, the biosimilar candidate to pembrolizumab, is under review by the FDA: the agency accepted the application in October 2026, the first publicly announced acceptance of an application for a pembrolizumab biosimilar. A regulatory decision is expected in the third quarter of 2027. In Canada, the application has also been submitted. For FYB208, the biosimilar candidate to dupilumab, Formycon is preparing for clinical development. FYB210 and FYB286 are at an early stage of development.

 

 

1 Tezspire® is a registered trademark of Amgen.

2 Hemlibra® is a registered trademark of Chugai Pharmaceutical, a member of the Roche Group.

3 Keytruda® is a registered trademark of Merck Sharp & Dohme, a subsidiary of Merck & Co.

4 Dupixent® is a registered trademark of Sanofi Biotechnology.

5 Sales in 2025 as reported by the manufacturers: Keytruda (including the subcutaneous formulation) USD 31.7 billion, Dupixent USD 17.8 billion, Hemlibra USD 5.7 billion (converted), Tezspire USD 1.9 billion.

6 https://www.astrazeneca.com/content/dam/az/PDF/2025/Q4-FY/Full-year-Q4-2025-results-announcement.pdf

7 https://www.who.int/en/news-room/fact-sheets/detail/chronic-obstructive-pulmonary-disease-%28copd%29

8 GlobalData, August 2026: https://finance.yahoo.com/healthcare/articles/amgen-astrazeneca-tezspire-nets-another-113014852.html; Leerink Partners, March 2025: https://www.fiercepharma.com/pharma/amgen-astrazeneca-tezspire-sinusitis-data-spark-best-disease-talk-amid-sanofi-gsk

9 https://www.roche.com/investors/updates/inv-update-2026-01-29

10 https://wfh.org/identification-and-diagnosis/

 

About Formycon:

Formycon AG is a listed, independent developer of biosimilars based in Martinsried, one of the leading life sciences locations in Europe, near Munich, Germany. Its 200 employees from 27 countries cover the entire development chain, from laboratory analysis and process development through clinical testing to the documents for approval. Formycon also manages manufacturing at partner sites and, for some products, the supply of finished goods. Three Formycon biosimilars are approved in ophthalmology and immunology and are marketed worldwide through commercialization partners. Five further candidates are in development, among them biosimilars to two of the best-selling biologic medicines in the world. With its products, Formycon makes highly effective therapies affordable for more people.

 

Formycon AG is listed in the Prime Standard of the Frankfurt Stock Exchange: FYB / ISIN: DE000A1EWVY8 / WKN: A1EWVY. Further information can be found at: www.formycon.com

 

About FYB4Growth:

With FYB4Growth, Formycon is pursuing a growth strategy based on four strategic pillars aimed at sustainable value creation. First, geographic diversification: in addition to Europe and the US, Formycon is expanding into high-growth regions such as MENA, APAC and Latin America through strong regional partners. Second, Formycon relies on a smart portfolio strategy that combines blockbuster molecules with selected niche products and creates the foundation for sustainable value generation through efficient regulatory development pathways. Third, Formycon positions itself as a technological and regulatory development powerhouse, creating clear competitive differentiation through innovative product solutions and new regulatory approaches. Fourth, Formycon focuses on consistent cost efficiency through streamlined processes, optimized development structures and the increased use of digital technologies, in order to enhance the scalability of its business model and strengthen its competitiveness over the long term. Further information can be found at: www.fyb4growth.de

 

About Biosimilars:

Biosimilars are successor products to biologic medicines. They are not copies; each one is developed from the ground up and must demonstrate to the health authorities that it has no clinically meaningful differences from the reference product in terms of safety and efficacy. According to the IQVIA Institute, 118 biologic medicines with sales of USD 232 billion will lose their exclusivity in the US alone by 2034, and for only twelve of them is a biosimilar in development. In Europe, biosimilars have saved EUR 75 billion and made more than seven billion days of treatment possible.

 

Contact
Dr. Jörg Allgäuer
Investor Relations &
Corporate Communications +49 89 864667‑107
 
Elena Straßner
Investor Relations +49 89 864667‑485
 
Thorsten Ladda
Corporate Communications +49 89 864667‑150
 
Formycon AG
Fraunhoferstr. 15 · 82152 Planegg-Martinsried · Germany
ir@formycon.com · www.formycon.com

 

Disclaimer:

The biosimilar candidates named in this release are investigational products and have not received regulatory approval in any country. Biosimilarity has not been established by regulatory authorities and is not claimed.

 

This release may contain forward-looking statements and information, which are based on the current expectations, estimates and assumptions of the management of Formycon AG. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, performance of Formycon AG, development of the products and the estimates given here.

 

Such known and unknown risks and uncertainties include, among others, risks relating to research and development, the regulatory approval process, the timing of the actions of regulatory bodies and other governmental authorities, clinical results, changes in laws and regulations, tariffs and trade policy, product quality, patient safety, the conclusion and performance of commercialization partnerships, market acceptance, pricing and competition, manufacturing and supply, including by third-party manufacturers, financing, including compliance with the covenants of the bond of Formycon AG, and the patents and exclusivities protecting reference products, including related litigation. With respect to pipeline products, Formycon AG does not make any representation, give any warranty or provide any other guarantee that the products will receive the necessary regulatory approvals or that they will prove to be commercially successful. Forward-looking statements should not be relied upon as predictions of future events. Formycon AG assumes no obligation to update these forward-looking statements or to correct them in case of developments which differ from those anticipated, except as required by law.

 

This release neither constitutes an offer to sell nor a solicitation of an offer to buy or subscribe for securities of Formycon AG in any jurisdiction, including the United States of America, Canada, Australia and Japan. No public offering of securities of Formycon AG will be made, or is intended, in connection with this release.


17.11.2026 CET/CEST Dissemination of a Corporate News, transmitted by EQS News – a service of EQS Group.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.


Language: English
Company: Formycon AG
Fraunhoferstraße 15
82152 Planegg-Martinsried
Germany
Phone: +49 89 864667 100
Fax: +49 89 864667 110
E-mail: ir@formycon.com
Internet: www.formycon.com
ISIN: DE000A1EWVY8, NO0013586024
WKN: A1EWVY, A4DFJH
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate BSX; Oslo
LEI Code: 39120005TZ76GQOY8Z19
EQS News ID: 2436182

 
End of News EQS News Service

2436182  17.11.2026 CET/CEST

Galimedix Therapeutics outlines development plans in Alzheimer’s disease at CTAD 2026

Galimedix, Inc.

/ Key word(s): Conference/Study

Galimedix Therapeutics outlines development plans in Alzheimer’s disease at CTAD 2026

16.11.2026 / 20:00 CET/CEST

The issuer is solely responsible for the content of this announcement.


Galimedix Therapeutics outlines development plans in Alzheimer’s disease at CTAD 2026
 

Kensington, MD, USA and Munich/Martinsried, Germany, November 16, 2026 – Galimedix Therapeutics, Inc. (“Galimedix”), a Phase 2 clinical-stage biotechnology company developing novel oral and topical neuroprotective therapies with the potential to revolutionize the treatment of serious brain and eye diseases, today announced that the Company is presenting new details on its planned Phase 2a development program to evaluate orally administered GAL-101 in patients with Alzheimer’s disease at the 19th Clinical Trials on Alzheimer’s Disease (CTAD) conference being held November 16-19, 2026 in Boston, MA.

Galimedix is planning to progress GAL-101 in Alzheimer’s disease through a focused development strategy, with the goal of establishing clinical proof of concept in a homogeneous patient population – Down syndrome-associated Alzheimer’s disease (DSAD) – while continuing to advance GAL-101 step-by-step in the general Alzheimer’s patient population, starting with a biomarker-based Phase 2a trial, SAPHARY.

The poster, “SAPHARY Phase 2a study to investigate the safety, efficacy, and pharmacokinetics of GAL-101 salt as oral treatment for patients with mild to moderate Alzheimer’s disease“, is focused on details of the SAPHARY Phase 2a trial (NCT07789873) in Alzheimer’s disease.  Given the advanced age, comorbidity burden, and disease-specific vulnerability of Alzheimer patients, this study aims to further characterize the safety and tolerability profile of GAL-101 and evaluate pharmacokinetic/pharmacodynamic (PK/PD) parameters as well as exploratory EEG readouts, fluid biomarkers and cognition endpoints. SAPHARY will be biomarker driven and is a 28-day, double-blind, randomized, multicenter, parallel group, placebo-controlled study that will enroll 100 patients with mild to moderate Alzheimer’s disease.

Hermann Russ, MD, PhD, Co-founder and Chief Scientific Officer of Galimedix, said: “Oral GAL-101 has been shown in clinical Phase 1 testing to be safe and well tolerated and effectively cross the blood-brain barrier. A robust pre-clinical package demonstrates GAL-101’s ability to prevent and eliminate all forms of toxic amyloid beta (Aβ) species while leaving healthy Aβ forms intact. GAL-101 has also demonstrated in Alzheimer’s disease models the potential for neuroprotection and alleviation of symptoms.

“With this strong foundation, we are now planning continued strategic development in Alzheimer’s, a highly heterogeneous disease that is in urgent need of new therapies that can slow or stop memory/cognition loss. Our plan includes a proof-of-concept trial in Down syndrome-associated Alzheimer’s disease, a homogeneous patient population that is associated with lifelong Aβ overproduction.  In addition, as outlined at CTAD, we are preparing a Phase 2a study in the general Alzheimer’s population to gain further insight into safety and PK/PD, as well as cognition and biomarker signals.  We are excited about the potential GAL-101 holds for helping patients who today have limited treatment options.”

About GAL-101
GAL-101 is a small molecule targeting misfolded amyloid beta (Aβ) monomers and thus preventing the formation of toxic Aβ oligomers and protofibrils. It is being developed in both oral and topical (eyedrops) formulations. Many studies have indicated that these soluble Aβ aggregates are a major underlying cause of neurodegenerative diseases of the brain and retina, and recent approvals of anti-Aβ drugs have also validated them as a key target in Alzheimer’s disease. GAL-101 is being developed for the treatment of Alzheimer’s disease, dry age-related macular degeneration (dAMD) and glaucoma.

In pre-clinical testing, the compound has been shown to prevent and eliminate all forms of toxic Aβ species while leaving healthy Aβ forms intact. GAL-101 has also demonstrated the potential for neuroprotection and for symptomatic alleviation in pre-clinical models of Alzheimer’s disease. Additionally, orally available GAL-101 has shown no antibody-specific immunological side effects (e.g., ARIA), very low systemic toxicity, robust storage stability, and easy and inexpensive manufacturing. Strong efficacy also has been demonstrated in relevant ophthalmic pre-clinical models, protecting neuronal retinal cells from toxic damage. In a previous Phase 1 study, GAL-101 eyedrops demonstrated an excellent safety and tolerability profile. The eDREAM Phase 2 study (NCT06659549) in dAMD/geographic atrophy with GAL-101 eyedrops is ongoing.

About Galimedix Therapeutics, Inc.
Galimedix is a Phase 2 clinical-stage private company developing novel oral and topical neuroprotective therapies with the potential to revolutionize the treatment of serious eye and brain diseases. Founded by a seasoned and highly dedicated team of bio-entrepreneurs, pharmaceutical executives and scientists, Galimedix’s groundbreaking small molecules offer the hope of changing the course of disease where amyloid beta plays a role, such as in dry age-related macular degeneration, glaucoma and Alzheimer’s disease – Galimedix’s initial areas of focus. For more information, visit www.galimedix.com and follow us on LinkedIn.

Contact
Alexander Gebauer, MD, PhD
Galimedix Therapeutics, Inc.
Co-founder and Executive Chairman
info@galimedix.com
Media inquiries
Anne Hennecke
MC Services AG
Tel: +49 (0) 170 7134018
galimedix@mc-services.eu
U.S.
Laurie Doyle
Tel: +1-339-832-0752

 


16.11.2026 CET/CEST Dissemination of a Corporate News, transmitted by EQS News – a service of EQS Group.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.


2435956  16.11.2026 CET/CEST

Viromed Medical AG Restructures Management Board for Its Next Growth Phase

Viromed Medical AG

/ Key word(s): Personnel

Viromed Medical AG Restructures Management Board for Its Next Growth Phase

16.11.2026 / 18:00 CET/CEST

The issuer is solely responsible for the content of this announcement.


Viromed Medical AG Restructures Management Board for Its Next Growth Phase

Rellingen, November 16, 2026 – The Supervisory Board of Viromed Medical AG (“Viromed”; ISIN: DE000A3MQR65) today resolved to appoint Christian Strauch to the Management Board of the company. Mr. Strauch assumes the position effective November 16, 2026, for a term of just under three years, until the end of October 31, 2029. At the same time, Uwe Perbandt, founder of Viromed Medical AG, has today resigned from his position on the Management Board, effective as of the end of December 31, 2026, for personal reasons.

Dr. Thomas Gutschlag, Chairman of the Supervisory Board of Viromed Medical AG: “The change on the Management Board takes place by mutual agreement with Uwe Perbandt. He shaped Viromed from the very beginning and, with tremendous commitment, developed the company into an internationally leading enterprise in the field of cold plasma technology. On behalf of the entire Supervisory Board, I extend my sincere thanks to him. With the recently achieved market readiness of Viromed’s technology, we now stand at the threshold of an exciting next growth phase for the company. We are convinced that Christian Strauch, with his well-founded sales expertise, is the ideal candidate to help shape this phase successfully.”

Uwe Perbandt, CEO of Viromed Medical AG: “For many years, I built Viromed with great passion and a highly dedicated team, and I am very proud of what we have achieved together. As a pioneer in medical technology, our cold plasma technology allows us to help many people and save many lives. That is all the more important to me because my life’s work, Viromed Medical AG, must be continued in the best possible way. With Christian Strauch, I am handing over responsibility to a highly experienced successor – my preferred candidate – and I leave the Management Board with a clear conscience.”

Christian Strauch is Managing Director of pharmedix GmbH, a subsidiary of Viromed. He has more than twenty years of experience in building and in scaling companies in the healthcare sector. Mr. Strauch built the mail-order pharmacy apo-rot, which grew to 450 employees and annual revenue of up to EUR 100 million, and oversaw the sale of its mail-order division to the Zur Rose Group or DocMorris (asset deal). As Managing Director of two DocMorris subsidiaries, Mr. Strauch led the integration of acquisitions, initiated the acquisition of medpex, and restructured the group’s procurement. Since 2020, he has been building the Vameda Group. He also founded two pharmaceutical wholesalers, which were sold to an investor group in 2024, and repositioned pharmedix GmbH as an omnichannel sales company, which Viromed acquired in 2024.

—-

About Viromed Medical AG

Viromed Medical AG specializes in the development, manufacture and distribution of medical products. The operating business of the company, which has been listed on the stock exchange since October 2022, focuses on the distribution of innovative cold plasma technology for medical applications via its wholly owned subsidiary Viromed Medical GmbH. Viromed can draw on a broad customer base in the DACH region and beyond. Viromed is pursuing the goal of further advancing the use of cold plasma technology in medicine in the coming years and realizing the corresponding growth potential.

www.viromed-medical-ag.de

Contact Viromed

E-Mail: kontakt@viromed-medical.de

Press contact

E-mail: viromed@kirchhoff.de


16.11.2026 CET/CEST Dissemination of a Corporate News, transmitted by EQS News – a service of EQS Group.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.


Language: English
Company: Viromed Medical AG
Hauptstraße 105
25462 Rellingen
Germany
E-mail: kontakt@viromed-medical.de
Internet: https://www.viromed-medical-ag.de/
ISIN: DE000A40ZVN7
WKN: A40ZVN
Listed: Regulated Unofficial Market in Dusseldorf, Frankfurt, Hamburg, Tradegate BSX
LEI Code: 894500XR05MYCVCCR171
EQS News ID: 2436146

 
End of News EQS News Service

2436146  16.11.2026 CET/CEST

Viromed Medical AG: Changes to the Management Board

Viromed Medical AG / Key word(s): Personnel decisions / Executive Board

Viromed Medical AG: Changes to the Management Board

16-Nov-2026 / 17:57 CET/CEST

Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by EQS News – a service of EQS Group.

The issuer is solely responsible for the content of this announcement.


Viromed Medical AG: Changes to the Management Board

Rellingen, November 16, 2026 – The Supervisory Board of Viromed Medical AG (“Viromed”; ISIN: DE000A40ZVN7) today resolved to appoint Christian Strauch to the Management Board of the company. Mr. Strauch assumes the position effective today, for a term of just under three years, until the end of October 31, 2029. Christian Strauch has more than twenty years of experience in building and in scaling companies in the healthcare sector.

At the same time, Uwe Perbandt, founder of Viromed Medical AG, has today resigned from his position on the Management Board, effective as of the end of December 31, 2026, for personal reasons.

 

Notifying person:

Uwe Perbandt, CEO of Viromed Medical AG

Contact Viromed:

E-mail: kontakt@viromed-medical.de

End of Inside Information


16-Nov-2026 CET/CEST The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.


Language: English
Company: Viromed Medical AG
Hauptstraße 105
25462 Rellingen
Germany
E-mail: kontakt@viromed-medical.de
Internet: https://www.viromed-medical-ag.de/
ISIN: DE000A40ZVN7
WKN: A40ZVN
Listed: Regulated Unofficial Market in Dusseldorf, Frankfurt, Hamburg, Tradegate BSX
LEI Code: 894500XR05MYCVCCR171
EQS News ID: 2436132

 
End of Announcement EQS News Service

2436132  16-Nov-2026 CET/CEST

Evotec Secures $2.9 Million Grant to Advance Early Drug Safety Testing Using Human Stem Cell Technology

Evotec SE

/ Key word(s): Miscellaneous

Evotec Secures $2.9 Million Grant to Advance Early Drug Safety Testing Using Human Stem Cell Technology

16.11.2026 / 07:30 CET/CEST

The issuer is solely responsible for the content of this announcement.


Evotec Secures $2.9 Million Grant to Advance Early Drug Safety Testing Using Human Stem Cell Technology
  • New three-year grant from the Gates Foundation extends a 2023 project to help global health researchers predict potential fetal development risks posed by novel drug candidates
  • Evotec’s human stem cell-based platform enables better-informed decisions regarding which drug candidates to advance into clinical testing
  • Continued collaboration underscores Evotec’s capabilities in advanced human cell-based drug discovery technologies
 

Hamburg, Germany, November 16, 2026 – Evotec SE (NASDAQ: EVO; Frankfurt Prime Standard: EVT) today announced that it has been awarded a new $2.9 million grant by the Gates Foundation to support continued use of its human stem cell-based New Approach Methodologies (NAMs) for identifying potential safety risks to fetal development in novel drug candidates. The funding extends a project initiated in 2023 for a further three years, providing researchers working on global health programs with continued access to technology that can help assess potential risks earlier in drug discovery.

Dr. Joanna Holbrook, Chief Scientific Officer of Evotec, said:

“Identifying potential safety risks early in the drug development process is essential to the efficient advancement of better medicines for global health priorities. Our platform allows researchers to investigate potential effects on prenatal development based on the behavior of human cells, helping them make better-informed decisions about which drug candidates to pursue and minimizing the risk of costly and time-consuming changes in course later in the process. The continued funding support of the Gates Foundation is an important recognition of the potential value of this approach, and we are pleased to extend access to this technology for global health research.”

Evotec’s platform combines human induced pluripotent stem cell (hiPSC) models with industrial-scale screening capabilities to model aspects of human development and to identify compounds that may pose developmental risks.

Over the course of the initial three-year collaboration, more than 5,000 compounds were screened across nine grantee programs, highlighting the platform’s ability to generate human-relevant safety data at scale. The development and validation of the platform are described in a recent bioRxiv preprint.

Evotec’s human stem cell-based platform forms part of its broader capabilities in New Approach Methodologies, which can potentially reduce reliance on animal testing and help improve research efficiency.
 

About Evotec’s New Approach Methodologies (NAMs)

Evotec is advancing a broad portfolio of human-relevant NAMs designed to support drug discovery and development. Leveraging more than 25 hiPSC-derived cellular models, advanced three-dimensional organoid systems, AI-supported disease modeling and industrial-scale screening platforms, Evotec generates high-quality data for both efficacy and safety assessment. These technologies aim to improve translational relevance and support more predictive decision-making throughout the drug discovery process.

About Evotec’s Human iPSC-Based Teratogenicity Platform

Evotec’s human iPSC-based teratogenicity hazard identification platform provides an in vitro, high-throughput approach for the assessment of potential developmental safety risks in drug discovery. Combining human stem cell-derived models with scalable screening technologies, such as automation and high-content imaging, the platform enables the generation of human-relevant data to support decision-making throughout the drug discovery process. As part of Evotec’s broader New Approach Methodology portfolio, which combines machine learning with high throughput experimentation, high content imaging and interpretable genome-scale molecular data to predict toxicology across organs, the platform is designed to help researchers identify potential safety liabilities earlier in development and advance more predictive, human-relevant approaches to drug discovery and safety assessment.

 

About Evotec SE

Evotec is a life science company pioneering the future of drug discovery and development. By integrating breakthrough science with AI-driven innovation and advanced technologies, Evotec accelerates the journey from concept to cure with greater speed, intelligence and precision. The company’s expertise spans small molecules, biologics, cell therapies and associated modalities, supported by proprietary platforms including Molecular Patient Databases, PanOmics and induced pluripotent stem cell-based disease modeling. Through flexible partnering models tailored to customers’ needs, Evotec works with all Top 20 pharmaceutical companies, more than 800 biotechnology companies, academic institutions and other healthcare stakeholders. Evotec’s offerings range from standalone services to fully integrated research and development programs and long-term strategic partnerships, combining scientific excellence with operational agility. Through Just – Evotec Biologics, the company is redefining biologics development and manufacturing to improve accessibility and affordability. With a portfolio of more than 100 proprietary research and development assets, most of which are co-owned, Evotec focuses on key therapeutic areas including oncology, cardiovascular and metabolic diseases, neurology and immunology. Evotec’s global team of around 4,500 experts operates from sites in Europe and the United States, providing complementary technologies and services through a network of synergistic centers of excellence. Learn more at www.evotec.com and follow Evotec on LinkedIn and X at @Evotec.

Forward-Looking Statements

This announcement contains forward-looking statements concerning future events, including Evotec’s financial results, full-year 2026 outlook, expected commercial conversion, anticipated strategic partnership and milestone contributions, Horizon implementation, expected cost savings, liquidity, financial flexibility and future business performance. Words such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “plan,” “potential,” “should,” “target,” “would” and variations of these words and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based on information available to Evotec and on expectations and assumptions considered reasonable by the company at the time the statements were made. No assurance can be given that these expectations will prove correct. Forward-looking statements involve known and unknown risks and are based on assumptions and estimates that are inherently subject to significant uncertainties and contingencies, many of which are beyond Evotec’s control. Evotec expressly disclaims any obligation or undertaking to publicly update or revise any forward-looking statements contained in this announcement to reflect changes in expectations, events, conditions or circumstances, except as required by applicable law.

Investor Relations and Media Contact

Dr. Sarah Fakih
EVP Head of Global Communications & Investor Relations
Sarah.Fakih@evotec.com

 


16.11.2026 CET/CEST Dissemination of a Corporate News, transmitted by EQS News – a service of EQS Group.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.


Language: English
Company: Evotec SE
Manfred Eigen Campus / Essener Bogen 7
22419 Hamburg
Germany
Phone: +49 (0)40 560 81-0
E-mail: info@evotec.com
Internet: www.evotec.com
ISIN: DE0005664809
WKN: 566480
Indices: SDAX, TecDAX
Listed: Regulated Market in Frankfurt (Prime Standard), Tradegate BSX; Regulated Unofficial Market in Dusseldorf, Hamburg, Hanover, Munich, Stuttgart; Nasdaq
LEI Code: 529900F9KI6OYITO9B12
EQS News ID: 2434956

 
End of News EQS News Service

2434956  16.11.2026 CET/CEST

Sofinnova Partners Closes €725M Crossover II Fund

Sofinnova Partners Closes €725M Crossover II Fund




Sofinnova Partners Closes €725M Crossover II Fund

  • Backing late-stage life sciences companies through to clinical development, global expansion and commercialization.
  • Positions Sofinnova to support approximately 15 high-growth companies, primarily in Europe, with selective investments in the U.S. and other markets.

PARIS–(BUSINESS WIRE)–Sofinnova Partners (“Sofinnova”), a leading European life sciences venture capital firm based in Paris, London, and Milan, today announced the final close of Sofinnova Crossover II at €725 million ($815 million USD).


The fund exceeded its original target, reflecting growing confidence in Sofinnova’s strategy of backing late-stage life sciences companies with the potential to become global leaders.

Sofinnova Crossover II will focus primarily on European clinical-stage biopharma and medtech companies seeking capital to advance toward commercialization. It will also invest in best-in-class companies in the United States and other international markets.

Antoine Papiernik, Chairman and Managing Partner of Sofinnova Partners, said: “The scale of this fund reflects both the maturity of the European life sciences ecosystem and the rising demand for capital that can help companies to reach global markets. Europe is producing a growing number of world-class life sciences companies, and we believe they should have access to investors that can support them through the critical stages of growth and commercialization.”

Sofinnova Crossover I has supported companies that have gone on to achieve significant value-creating milestones, including, LimFlow (acquired by Inari Medical), Calliditas Therapeutics (acquired by Asahi Kasei), Amolyt Pharma (acquired by AstraZeneca), and Abivax (Nasdaq listing). These outcomes demonstrate that strategy’s ability to help late-stage companies navigate the path from clinical development to global scale.

Kinam Hong, Partner at Sofinnova Partners, commented: “We continue to see exceptional opportunities emerging across European life sciences. Many companies now have scientific strength, clinical validation, and leadership teams needed to compete on a global stage. With Sofinnova Crossover II, we are well positioned to support that next generation of leaders while maintaining the disciplined investment approach that defined our first fund.”

With Crossover II, Sofinnova further strengthens its position as one of Europe’s leading dedicated crossover investors in life sciences. The fund has already backed Hemab Therapeutics, CellCentric and Neurent Medical and expects to invest in approximately 15 companies over its investment period, with a primary focus on Europe and selective investments globally.

The strategy is led by Partners Joe Anderson, Kinam Hong, Cedric Moreau, Jacques Theurillat, and David Evans. The fund is backed by the European Tech Champions Initiative (ETCI), a fund of funds managed by the European Investment Fund (EIF).

About Sofinnova Partners

Sofinnova Partners is a leading European venture capital firm in life sciences, specializing in healthcare and sustainability. Based in Paris, London and Milan, the firm brings together a team of professionals from all over the world with strong scientific, medical and business expertise. Sofinnova Partners is a hands-on company builder across the entire value chain of life-sciences investments, from seed to later-stage. Founded in 1972, Sofinnova Partners has over 50 years of experience backing over 500 companies and creating market leaders around the globe. Today, Sofinnova Partners manages over €4 billion in assets. For more information, please visit: sofinnovapartners.com.

Contacts

Sofinnova Partners
Bommy Lee
Head of Communications

blee@sofinnovapartners.com
+33 (0) 6 47 71 38 11

Media inquiries:

United Kingdom
Optimum Strategic Communications

Eleanor Cooper

sofinnova@optimumcomms.com
+44 (0) 20 4604 4016

France
Strategies&Image (S&I)

Anne Rein

anne.rein@strategiesimage.com
+33 (0) 6 03 35 92 05

Italy
Havas PR Milan

Pierluigi Cavarai

pierluigi.cavarai-ext@havaspr.com
+39 (0) 392 77 999 33

Sandoz launches Enzeevu in the US and announces key private label agreement, expanding treatment choice for patients with retinal diseases

Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules

MEDIA RELEASE
 

  • Provides additional treatment option for patients living with various retinal diseases
  • Multi-year private-label agreement will substantially expand reach and sales growth in US from next year
  • Reinforces commitment to Bio100 ambition, with goal to have more than 100 biosimilars in portfolio by 2040

 

Basel, 16 November 2026 – Sandoz (SIX:SDZ/OTCQX:SDZNY), the global leader in affordable medicines, today announced the US launch of Enzeevu® (aflibercept-abzv) 2 mg, approved in a pre-filled syringe. Enzeevu is approved to treat various retinal diseases including neovascular (wet) age-related macular degeneration (nAMD), macular edema following retinal vein occlusion (RVO), diabetic retinopathy (DR) and diabetic macular edema (DME), which collectively impact more than 30 million Americans1.

Keren Haruvi, President Sandoz North America, says: “Vision loss caused by retinal diseases can have a profound impact on patients, their families and their quality of life. Yet, for many, the cost of treatment remains a significant barrier to care. With the US launch of Enzeevu, we are adding a biosimilar treatment option that supports broader access and healthcare system sustainability.”

Retinal diseases are among the leading causes of vision loss in people over age 50 and can substantially affect patients and their families, including mobility, independence and daily activities, health, social connection, work and education2. Expanding the availability of treatment options may help support the continuity of retinal care2.

Sandoz received FDA approval for Enzeevu in August 20243. It is FDA-approved in the same dosage form, route of administration and presentation as the reference medicine, Eylea®* (aflibercept)3. Enzeevu® is proven to be clinically equivalent in terms of efficacy and safety to the reference medicine and has met all FDA requirements for biosimilarity3-7. It is also interchangeable with the reference medicine for all approved indications, providing patients and providers with a more affordable treatment option.

Alongside the US own-label launch, Sandoz has entered into a multi-year private-label agreement for Enzeevu, creating an additional commercial channel for the medicine in the US. Under the agreement, Sandoz will manufacture Enzeevu for commercialisation under a private label beginning in mid-2027.

The agreement builds on the Sandoz track record of successfully launching multiple private-label biosimilars in the US, including the first-ever biosimilar private label, and reflects the Company’s disciplined approach to commercialisation. It also provides committed volumes beginning in the second half of 2027.

The launch of Enzeevu strengthens the Sandoz position in ophthalmology, following the acquisition of US biosimilar Cimerli® (ranibizumab-eqrn) in 2024 and the European launch of Afqlir® (aflibercept) in 2025, and comes in a US anti-VEGF market worth an estimated USD 9.6 billion. It leverages Sandoz experience in ophthalmology and its legacy in biosimilars and continues its strong momentum in biosimilars in the US.

The launch also reflects the Sandoz commitment to its Bio100 ambition, which targets more than 100 biosimilars in the portfolio by 2040, nearly doubling current biosimilar loss-of-exclusivity coverage to around 80% from 2035 onwards. Through Bio100, Sandoz aims to broaden access to high-quality, affordable biosimilars for patients worldwide.

*Eylea® is a registered trademark of Regeneron Pharmaceuticals, Inc. Ltd

 

ABOUT Enzeevu

The active ingredient in Enzeevuis aflibercept. Aflibercept is a recombinant fusion protein that binds to vascular endothelial growth factor A and placental growth factor, inhibiting abnormal vessel growth. In patients with nAMD, macular edema following RVO, DR and DME, aflibercept is administered into the eye as an intravitreal injection helping to inhibit abnormal blood vessel growth and reduce vascular permeability associated with retinal diseases4.

 

INDICATIONS

Enzeevuinjection, for intravitreal use, is indicated for the treatment of patients with nAMD), macular edema RVO, DR and DME.

 

SELECT IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS: Enzeevu is contraindicated in patients with ocular or periocular infections, active intraocular inflammation, or known hypersensitivity to aflibercept or to any of the ingredients in Enzeevu.

 

WARNINGS AND PRECAUTIONS: Endophthalmitis, retinal detachments and retinal vasculitis with or without occlusion may occur following intravitreal injections. Patients and/or caregivers should be instructed to report any signs and/or symptoms suggestive of these events without delay and should be managed appropriately; increases in intraocular pressure have been observed within 60 minutes of an intravitreal injection. There is a potential risk of arterial thromboembolic events following intravitreal use of vascular endothelial growth factor inhibitors

 

ADVERSE REACTIONS: The most common adverse reactions (≥5%) reported in patients receiving aflibercept were conjunctival haemorrhage, eye pain, cataract, vitreous detachment, vitreous floaters and intraocular pressure increased

 

This is not the complete list of all the safety information for Enzeevu. Please see full Prescription Information for Enzeevu.

 

Select Important Safety Information

INDICATIONS

Cimerli injection, for intravitreal use, is indicated for the treatment of patients with nAMD; macular edema following RVO; DME; DR; Myopic Choroidal Neovascularisation.

 

CONTRAINDICATIONS: ocular or periocular infections, hypersensitivity

 

WARNINGS AND PRECAUTIONS: endophthalmitis and retinal detachments may occur following intravitreal injections. Patients should be monitored following the injection; increases in intraocular pressure have been noted both pre- and post-intravitreal injection; there is a potential risk of arterial thromboembolic events following intravitreal use of VEGF inhibitors; fatal events occurred more frequently in patients with diabetic macular edema and diabetic retinopathy at baseline, who were treated monthly with ranibizumab compared with control

 

ADVERSE REACTIONS: The most common adverse reactions (reported more frequently in ranibizumab-treated subjects than control subjects) are conjunctival haemorrhage, eye pain, vitreous floaters, and increased IOP

 

This is not the complete list of all the safety information for Cimerli. Please see full Prescribing Information.

 

DISCLAIMER
This Media Release contains forward-looking statements, which offer no guarantee with regard to future performance. These statements are made on the basis of management’s views and assumptions regarding future events and business performance at the time the statements are made. They are subject to risks and uncertainties including, but not confined to, future global economic conditions, exchange rates, legal provisions, market conditions, activities by competitors and other factors outside of the control of Sandoz. Should one or more of these risks or uncertainties materialise or should underlying assumptions prove incorrect, actual outcomes may vary materially from those forecasted or expected. Each forward-looking statement speaks only as of the date of the particular statement, and Sandoz undertakes no obligation to publicly revise any forward-looking statements, except as required by law.

REFERENCES
1 Retinal disease prevalence study reveals gaps. PentaVision. Available at: https://retinalphysician.com/issues/2026/march-april/retinal-disease-prevalence-study-reveals-gaps/ [Last accessed: November 2026]

2 Hariprasad S, Holz F, Asche C, et al. Clinical and Socioeconomic Burden of Retinal Diseases: Can Biosimilars Add Value? A Narrative Review. Ophthalmol Ther. 2025 Feb 26;14(4):621–641. doi: 10.1007/s40123-025-01104-3 [Last accessed: November 2026]

3 Sandoz receives FDA approval for Enzeevu™ (aflibercept-abzv), further strengthening US biosimilar position. August 2024. https://www.sandoz.com/us-en/news/sandoz-receives-fda-approval-enzeevutm-aflibercept-abzv-further-strengthening-us-biosimilar/ [Last accessed: November 2026]

4 Enzeevu®. Prescribing Information. Available at: https://pro-enzeevu-com.cms.sandoz.com/sites/default/files/Media%20Documents/ENZEEVU_PI_04-05-2026%201.pdf [Last accessed: November 2026]

5 Dodeller F, Alliger P, Heyn J, et al. Development of Biosimilar Aflibercept SDZ-AFL. Current Therapeutic Research. 2025;103:100812.

6 Bordon AF, Kaiser PK, Wolf A, et al. Efficacy and safety of the proposed biosimilar aflibercept, SDZ-AFL, in patients with neovascular age-related macular degeneration: 52-week results from the Phase 3 Mylight study. Retina. 2024;44(10):1704-1713.

7 US Food and Drug Administration. Biosimilar Product Regulatory Review and Approval. FDA.gov. Updated Sep 2017. Available at: https://www.fda.gov/files/drugs/published/Biosimilar-Product-Regulatory-Review-and-Approval.pdf [Last accessed: November 2026]

ABOUT SANDOZ
Sandoz (SIX: SDZ; OTCQX: SDZNY) is the global leader in affordable medicines, with a growth strategy driven by its Purpose: pioneering access for patients. More than 20,000 colleagues of 100 nationalities work together to ensure over one billion patients are reached by Sandoz, generating substantial global healthcare savings and an even larger social impact. Its leading portfolio of approximately 1,300 medicines addresses diseases from the common cold to cancer. Headquartered in Basel, Switzerland, Sandoz traces its heritage back to 1886. In 2026, Sandoz celebrates 20 years of pioneering biosimilars, 80 years of antibiotics manufacturing and 140 years of heritage. In 2025, Sandoz recorded net sales of USD 11.1 billion.  

 

CONTACTS

Global Media Relations contacts

Investor Relations contacts

Global.MediaRelations@sandoz.com

Investor.Relations@sandoz.com

Alexis Kalomparis

+41 792 790285

Craig Marks

+44 7818 942 383

Marina Konrad-Maerk

+41 79 487 79 89

Tamara Hackl

+41 79 790 5217

Gregor Rodehueser

+49 170 574 3200

Silvia Siegfried

+41 79 795 9061

US Media Relations contacts

 

Jeanne LaCour

+1 609 955 2339

 

Vicki Crafton

+1 201 213 6338